- Home
- PCSA vs UOKA Comparison
PCSA vs UOKA Comparison
Compare PCSA & UOKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- UOKA
- Stock Information
- Founded
- PCSA 2011
- UOKA 2002
- Country
- PCSA United States
- UOKA United Kingdom
- Employees
- PCSA N/A
- UOKA N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- UOKA
- Sector
- PCSA Health Care
- UOKA
- Exchange
- PCSA Nasdaq
- UOKA NYSE
- Market Cap
- PCSA 2.8M
- UOKA 2.6M
- IPO Year
- PCSA N/A
- UOKA N/A
- Fundamental
- Price
- PCSA $0.45
- UOKA $0.16
- Analyst Decision
- PCSA Strong Buy
- UOKA
- Analyst Count
- PCSA 1
- UOKA 0
- Target Price
- PCSA $6.00
- UOKA N/A
- AVG Volume (30 Days)
- PCSA 105.2K
- UOKA 10.9M
- Earning Date
- PCSA 03-28-2025
- UOKA 03-25-2025
- Dividend Yield
- PCSA N/A
- UOKA N/A
- EPS Growth
- PCSA N/A
- UOKA N/A
- EPS
- PCSA N/A
- UOKA N/A
- Revenue
- PCSA N/A
- UOKA $114,849.00
- Revenue This Year
- PCSA N/A
- UOKA N/A
- Revenue Next Year
- PCSA N/A
- UOKA N/A
- P/E Ratio
- PCSA N/A
- UOKA N/A
- Revenue Growth
- PCSA N/A
- UOKA 289.97
- 52 Week Low
- PCSA $0.42
- UOKA $0.13
- 52 Week High
- PCSA $3.31
- UOKA $1.80
- Technical
- Relative Strength Index (RSI)
- PCSA 28.32
- UOKA N/A
- Support Level
- PCSA $0.44
- UOKA N/A
- Resistance Level
- PCSA $0.54
- UOKA N/A
- Average True Range (ATR)
- PCSA 0.05
- UOKA 0.00
- MACD
- PCSA 0.00
- UOKA 0.00
- Stochastic Oscillator
- PCSA 16.03
- UOKA 0.00
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About UOKA MDJM LTD
MDJM Ltd is a real estate service company. The company provides real estate agency services to real estate developer clients, as well as real estate consulting services and independent training services on an as-needed basis. It offers consulting, marketing planning, advertising services, and sales strategies to real estate clients. The company income is derived from commission-based services and minimal consulting and other services. The company has two operating segments; the real estate agent services segment and the hospitality business segment. It derives a majority of its revenue from the People's Republic of China.